Abstract:The human enteropathogen Clostridium difficile constitutes a key public health issue in industrialized countries. Many aspects of C. difficile pathophysiology and adaptation inside the host remain poorly understood. We have recently reported that this bacterium possesses an active CRISPR-Cas system of subtype I-B for defense against phages and other mobile genetic elements that could contribute to its success during infection. In this paper, we demonstrate that redirecting this endogenous CRISPR-Cas system toward autoimmunity allows efficient genome editing in C. difficile . We provide a detailed description of this newly developed approach and show, as a proof of principle, its efficient application for deletion of a specific gene in reference strain 630Δ erm and in epidemic C. difficile strain R20291. The new method expands the arsenal of the currently limiting set of gene engineering tools available for investigation of C. difficile and may serve as the basis for new strategies to control C. difficile infections. IMPORTANCE Clostridium difficile represents today a real danger for human and animal health. It is the leading cause of diarrhea associated with health care in adults in industrialized countries. The incidence of these infections continues to increase, and this trend is accentuated by the general aging of the population. Many questions about the mechanisms contributing to C. difficile 's success inside the host remain unanswered. The set of genetic tools available for this pathogen is limited, and new developments are badly needed. C. difficile has developed efficient defense systems that are directed against foreign DNA and that could contribute to its survival in phage-rich gut communities. We show how one such defense system, named CRISPR-Cas, can be hijacked for C. difficile genome editing. Our results also show a great potential for the use of the CRISPR-Cas system for the development of new therapeutic strategies against C. difficile infections.

Identification of an anti-CRISPR protein that inhibits the CRISPR-Cas type I-B system in Clostridioides difficile

New Insights Into Functions and Possible Applications of Clostridium difficile CRISPR-Cas System

Using an Endogenous CRISPR-Cas System for Genome Editing in the Human Pathogen Clostridium difficile

An enterococcal phage protein inhibits type IV restriction enzymes involved in antiphage defense

The novel anti-CRISPR AcrIIA22 relieves DNA torsion in target plasmids and impairs SpyCas9 activity

Inhibition of CRISPR-Cas9 with Bacteriophage Proteins

CRISPR-repressed toxin-antitoxin provides population-level immunity against diverse anti-CRISPR elements

CRISPR-repressed toxin-antitoxin provides herd immunity against anti-CRISPR elements

An enterococcal phage protein broadly inhibits type IV restriction enzymes involved in antiphage defense

Structural insights into the inactivation of the type I-F CRISPR-Cas system by anti-CRISPR proteins

Conjugative Delivery of CRISPR-Cas9 for the Selective Depletion of Antibiotic-Resistant Enterococci

Dairy phages escape CRISPR defence of Streptococcus thermophilus via the anti-CRISPR AcrIIA3

Bacteriophage Cooperation Suppresses CRISPR-Cas3 and Cas9 Immunity

Exploiting a Conjugative Endogenous CRISPR-Cas3 System to Tackle Multidrug-Resistant Klebsiella Pneumoniae.

Broad-spectrum anti-CRISPR proteins facilitate horizontal gene transfer

Functional metagenomics-guided discovery of potent Cas9 inhibitors in the human microbiome

CRISPR-based antimicrobials to obstruct antibiotic-resistant and pathogenic bacteria

Potent Cas9 inhibition in bacterial and human cells by new anti-CRISPR protein families

Mechanistic insights into the inhibition of the CRISPR-Cas surveillance complex by anti-CRISPR protein AcrIF13

A Type I-F Anti-CRISPR Protein Inhibits the CRISPR-Cas Surveillance Complex by ADP-Ribosylation

Diverse viral cas genes antagonize CRISPR immunity